drugset / Trial / NCT00534417
Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Phase 2
Completed
41 enrolled
Accelerated Community Oncology Research Network
AstraZeneca · collabHoffmann-La Roche · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if the combination of continuous daily capecitabine with fulvestrant on a loading dose schedule will delay disease progression in metastatic breast cancer (MBC) patients.
Timeline
- Start
- 2007-10
- Primary completion
- 2011-09
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1500 mg | Oral |
| Subject | Capecitabine | Small molecule | 2000 mg | Oral |
| Subject | Fulvestrant | Small molecule | 250 mg | — |